OSE Immunotherapeutics SA

OSE.EU

$5.42

Closing

▲5.15%

1D

▲16.82%

YTD

Market cap

$116.95M

52 week high

$7.92

52 week low

$2.93

Volume

387,373

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

$116.95M

Analysts' Rating

BUY

Price Target (Mean)

9.132516621

Total Analysts

0

P/E

Operating Margin

-994.40%

Beta

0.66

Revenue Growth (Annual)

-38.04%

52 week high

$7.92

52 week low

$2.93

Div. Yield

0.00%

EPS Annual Growth

0.00

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

OSE Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company, engaged in clinical stage biotechnological sector. It develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The Company’s research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. It provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.